Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline ...

Sensei Biotherapeutics, Inc. SNSE surged on Wednesday following the company’s announcement of its acquisition of Faeth Therapeutics Inc. and a concurrent $200 million private investment. The ...

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company. | Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling ...

The company also secured a private placement financing worth around $200 million. ・Sensei Biotherapeutics plans to use the majority of the proceeds to advance PIKTOR. ・Remaining funds will be used for ...

Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials These results suggest that common genetic variations ...

Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline Agents inhibiting the phosphoinositide ...

Investing.com -- Sensei Biotherapeutics (NASDAQ:SNSE) stock soared 200% Wednesday after the company announced its acquisition of Faeth Therapeutics and a concurrent $200 million private placement.

Antioxidant-1 may promote HCC carcinogenesis through the activation of the c-Myb/PI3K/AKT pathway and the inhibition of copper accumulation and oxidative stress. Despite advancements in diagnostic and ...

Oral presentation to highlight updated Phase 1 monotherapy safety and efficacy data for TOS-358, a covalent PI3Ka inhibitorData will include ...